MDxHealth, Inc. Appoints Walter Narajowski As Independent Director
IRVINE, CA, and HERSTAL, BELGIUM - October 5, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announces that it has strengthened its Board of Directors with the appointment of Mr. Walter Narajowski, a medical diagnostics business leader with over 25 years of industry experience.
Mr. Narajowski brings significant experience to MDxHealth in the launch and successful global commercialization of molecular diagnostics from across the industry, from infectious diseases to food safety. He is currently Senior Vice President / General Manager of Roka Bioscience, a molecular diagnostic company developing tests and instrument systems for the food industry. Prior to Roka, Mr. Narajowski was Chief Executive Officer of Pathway Diagnostics, a biomarker development and testing company, which was subsequently sold to Quest Diagnostics.
For the majority of his career, Mr. Narajowski was with Abbott Laboratories where he served in a number of key positions, including Vice President, General Manager of Critical Care Products, Vice President, General Manager of Abbott's infusion pump business, and General Manager of Physician Office Diagnostics, and Director of Research and Development in Abbott Diagnostics. Mr. Narajowski received his MS in bioengineering from the University of Utah, and his BS in electrical engineering from the Illinois Institute of Technology.
The Company also announces that Mr. Mark Myslinski has stepped down from the Board after five years of dedicated service to MDxHealth.
Mr. Edward L. Erickson, Chairman of the Board of MDxHealth, commented: "We are delighted to have attracted such an accomplished and experienced diagnostics industry leader to our Board. Walter will be integral to guiding MDxHealth as we grow our global commercial presence and bring new tests to market.
"On behalf of the Board, I thank Mark for his many contributions to MDxHealth. His experience has been vital as we evolved from a research-focused company to become a successful commercial business. We wish him well in all of his future endeavors."
As a result of the aforementioned changes, the MDxHealth Board now consists of:
• Greenlands Consulting L.L.C., represented by Mr. Edward L. Erickson, Chairman of the Board of Directors and Independent Director
• Dr. Jan Groen, Chief Executive Officer and Executive Director
• Mrs. Ruth Devenyns, Independent Director
• Lab Dx L.L.C., represented by Mr. Walter Narajowski, Independent Director
• Gengest BVBA, represented by Mr. Rudi Mariën, Non-Executive Director
• Valiance Advisors LLP, represented by Mr. Jan Pensaert, Non-Executive Director
Following the recent acquisition of NovioGendix, Prof. Dr. Jack Schalken will also serve as an independent advisor to the Company and the Board of Directors.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth. For more information:
Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
Cell: + 44 7739658783
fennell@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.
Mr. Narajowski brings significant experience to MDxHealth in the launch and successful global commercialization of molecular diagnostics from across the industry, from infectious diseases to food safety. He is currently Senior Vice President / General Manager of Roka Bioscience, a molecular diagnostic company developing tests and instrument systems for the food industry. Prior to Roka, Mr. Narajowski was Chief Executive Officer of Pathway Diagnostics, a biomarker development and testing company, which was subsequently sold to Quest Diagnostics.
For the majority of his career, Mr. Narajowski was with Abbott Laboratories where he served in a number of key positions, including Vice President, General Manager of Critical Care Products, Vice President, General Manager of Abbott's infusion pump business, and General Manager of Physician Office Diagnostics, and Director of Research and Development in Abbott Diagnostics. Mr. Narajowski received his MS in bioengineering from the University of Utah, and his BS in electrical engineering from the Illinois Institute of Technology.
The Company also announces that Mr. Mark Myslinski has stepped down from the Board after five years of dedicated service to MDxHealth.
Mr. Edward L. Erickson, Chairman of the Board of MDxHealth, commented: "We are delighted to have attracted such an accomplished and experienced diagnostics industry leader to our Board. Walter will be integral to guiding MDxHealth as we grow our global commercial presence and bring new tests to market.
"On behalf of the Board, I thank Mark for his many contributions to MDxHealth. His experience has been vital as we evolved from a research-focused company to become a successful commercial business. We wish him well in all of his future endeavors."
As a result of the aforementioned changes, the MDxHealth Board now consists of:
• Greenlands Consulting L.L.C., represented by Mr. Edward L. Erickson, Chairman of the Board of Directors and Independent Director
• Dr. Jan Groen, Chief Executive Officer and Executive Director
• Mrs. Ruth Devenyns, Independent Director
• Lab Dx L.L.C., represented by Mr. Walter Narajowski, Independent Director
• Gengest BVBA, represented by Mr. Rudi Mariën, Non-Executive Director
• Valiance Advisors LLP, represented by Mr. Jan Pensaert, Non-Executive Director
Following the recent acquisition of NovioGendix, Prof. Dr. Jack Schalken will also serve as an independent advisor to the Company and the Board of Directors.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth. For more information:
Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
Cell: + 44 7739658783
fennell@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.